Phase 1 Evaluation of VIS171 Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity in Autoimmune Conditions: Alopecia Areata, Systemic Lupus Erythematosus, and Immune-Mediated Focal Segmental Glomerulosclerosis

The primary objective of this phase 1 trial is to evaluate the **safety**, **tolerability**, **pharmacodynamics**, **pharmacokinetics**, and **immunogenicity** of VIS171 in participants with autoimmune diseases, specifically **Alopecia Areata**, **Systemic Lupus Erythematosus**, and **Immune-mediated Focal Segmental Glomerulosclerosis**. Understanding these parameters is crucial for determining the potential therapeutic benefits and risks associated with VIS171, which may inform future clinical development and treatment strategies for these conditions.

The clinical trial involves a total of **9 participants** diagnosed with conditions such as **Alopecia Areata**, **Systemic lupus erythematosus**, and **Immune-mediated focal segmental glomerulosclerosis**. The study population includes both male and female subjects, with an age range that spans from children to adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune diseases, specifically **Alopecia Areata**, **Systemic lupus erythematosus**, and **Immune-mediated focal segmental glomerulosclerosis**. This is a Phase 3 trial, which will be conducted as a randomized, double-blind, controlled study. The estimated recruitment start date is May 26, 2025, with an anticipated end date of October 30, 2026, indicating an overall trial duration of approximately 17 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the participants' response to the treatment and to collect data on the primary and secondary endpoints. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the long-term effects and safety of the investigational product.

The expected length of participant involvement will vary depending on the specific protocol schedule, but it is anticipated to span the entire duration of the trial. Conditions that may lead to early termination from the study include adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is structured to ensure rigorous data collection and analysis, adhering to ethical standards and regulatory requirements.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current information.

Similarly, there is no data available concerning any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in the current context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 26, 2025, with an estimated completion date of October 30, 2026. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger population. The trial's design will ensure that efficacy is assessed objectively and consistently throughout the study duration.